The total cholesterol 4,09,0 mmol / l, triglycerides <6.0 mmol / l and sohrannaya didactic function criteria were included in this study. These few cohort studies suggest that statins lipidsnizhayuschaya therapy by nearly 70% reduction in the risk of developing dementia. Therefore, in addition to other purposes, the study will explore the impact of PROSPER pravastatina the frequency of dementia. Thus, for the first time will study the impact gipolipidemicheskoy therapy not only on the frequency of serdechnososudistyh complications from a particular group of people aged 7082 years, but at the risk of cerebral stroke and dementia. Another critical issue of treatment of patients with cerebrovascular disease is to prevent the repetition of the cerebral circulation. Effect of aggressive therapy lipidsnizhayuschey atorvastatinom 80 mg / day to placebo in the risk of cerebrovascular (primary objective) and cardiovascular (secondary objective) complications in patients with stroke or brain transferred transient ischaemic attack (TIA) in history will be examined in the study SPARCL. A feature of this study is the inclusion of patients with IBS and manifestations defeat trunk receptacles lower limbs, as well as the exclusion of patients with kardioembolicheskimi think insultami and TIA. The study is scheduled to attend about 4200 patients over 18 years of age with documented brain stroke or TIA within 16 months prior to randomization, to the level of low-density lipoprotein 100190 mg / dl (2,64,9 mmol / l). Estimated duration of observation about 5 years. If the study SPARCL main hypothesis is proved, the guidance on patients with human cerebral circulation without clinical manifestation of atherosclerosis and coronary artery trunk receptacles lower limbs will be significant additions.